Sacubitril/valsartan and cardiac injury/stress and systemic inflammatory biomarkers in acute heart failure: a prespecified secondary analysis of the PREMIER study

Clicks: 19
ID: 328512
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #13 of 49 articles by views in European Heart Journal - Cardiovascular Pharmacotherapy

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
AIMS: Acute heart failure (AHF) is accompanied by myocardial injury, wall stress, and systemic inflammatory activation. Whether initiating sacubitril/valsartan (Sac/Val) after haemodynamic stabilization modifies cardiac injury/stress and systemic inflammatory biomarkers is uncertain. METHODS AND RESULTS: The Program Angiotensin-Neprilysin Inhibition in Admitted Patients with Worsening Heart Failure (PREMIER) study was a multicentre, prospective, randomised, open-label trial with blinded endpoint assessment. Within 7 days of hospitalisation and after haemodynamic stabilisation, inpatients previously treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) were randomised to switch to Sac/Val or continue ACEI/ARB. In this pre-specified secondary analysis, high-sensitivity cardiac troponin T (hs-cTnT), soluble ST2 (sST2), C-reactive protein (CRP), and growth differentiation factor-15 (GDF-15) were measured at baseline and week 8. N-terminal pro-B-type natriuretic peptide (NT-proBNP) was also assessed. Among 365 patients with complete cardiac injury/stress and systemic inflammatory biomarker data, all biomarkers generally decreased over 8 weeks, but between-group differences in biomarker changes were not significant. In exploratory biomarker-stratified analyses, only baseline CRP showed a nominal treatment interaction for NT-proBNP (p for interaction=0.012). CONCLUSION: In haemodynamically stabilised patients hospitalised for AHF, no differential effects of Sac/Val versus continued ACEI/ARB therapy on cardiac injury/stress and systemic inflammatory biomarkers were demonstrated over 8 weeks. These findings do not support a broad biomarker-defined anti-inflammatory or cardioprotective effect of Sac/Val in this setting.
Reference Key
openalex_W7212257212 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shunichi Doi, Atsushi Tanaka, Takumi Imai, Yoshihiro J. Akashi, Teruhiro Sakaguchi, Masayoshi Ajioka, Takenori Ikoma, Yuichiro Maekawa, Nobuhiro Tanaka, Yuya Matsue, Keisuke Kida, Koichi Node
Are you one of these authors? Claim your profile
Journal European Heart Journal - Cardiovascular Pharmacotherapy
Year 2026
DOI
10.1093/ehjcvp/pvag076
URL
https://doi.org/10.1093/ehjcvp/pvag076
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.